Every S-3 that Cue Biopharma Inc (CUE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow CUE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CUE filings page.
Cue Biopharma, Inc. filed a shelf registration to permit the resale by existing investors of up to 1,505,570 shares of common stock. The registered shares comprise 1,418,070 shares issued in a July 2026 private placement and 87,500 shares issuable upon exercise of outstanding Pre-Funded Warrants with a cash exercise price of $0.001 per share.
The investors originally purchased the securities for aggregate gross proceeds of approximately $50.0 million at $33.21 per share (or $33.209 per Pre-Funded Warrant). Cue Biopharma will not receive proceeds from any resale of these shares, other than nominal cash received upon warrant exercises. As of July 24, 2026, 6,826,387 shares of common stock were outstanding. The company’s independent auditor’s report for 2024–2025 includes an explanatory paragraph regarding the company’s ability to continue as a going concern.
Cue Biopharma, Inc. registers 551,724 shares of common stock for resale by Ascendant Health Sciences, Ltd. These 551,724 shares are issuable upon exercise of pre-funded warrants and are being registered for resale by the selling stockholder; the company will not receive proceeds from those resale transactions except nominal proceeds equal to the $0.001 cash exercise price per share for any Pre-Funded Warrants exercised for cash. The Pre-Funded Warrants were issued as partial consideration under a Securities Purchase Agreement dated April 30, 2026. As context, shares outstanding were 4,200,343 as of June 1, 2026, and the last reported sale price on June 17, 2026 was $26.73 per share.
Cue Biopharma, Inc. files a registration to permit resale of up to 4,090,908 shares of common stock by selling stockholders, consisting of 2,727,272 shares issuable upon exercise of Pre-Funded Warrants and 1,363,636 shares issuable upon exercise of Warrants. The company states it will not receive proceeds from resales, except for any $11.00 per-share cash exercise of the Warrants. The shares were issued in a private placement that closed on May 4, 2026; the registration implements contractual resale and registration rights and remains subject to the resale limitations and beneficial ownership caps described in the warrants.
Cue Biopharma, Inc. has filed an S-3 registration statement to register up to $300,000,000 of securities, covering debt, common and preferred stock, subscription rights, units and warrants. The filing also includes an at-the-market sales agreement with Jefferies to sell up to $12,666,282 of common stock from time to time.
The prospectus states the ATM agent fee is 3.0% of gross proceeds and cites a public float of $37,998,848 based on March 13, 2026 and 97,283,278 shares held by non-affiliates. The prospectus emphasizes that specific terms for any offering will be set forth in prospectus supplements and warns of the risks described under "Risk Factors."